Categories
and Concern General Health

IBD treatment by MEK Could Lower Transcriptional Inflammation Score

Increasing autoimmune diseases and inflammatory diseases occur globally every year and at least 50 million people have suffered an autoimmune disease amongst Americans, according to the American Autoimmune Related Diseases Association (AARDA). Autoimmune diseases are the third most common diseases along with cancer, and heart disease.

Researchers found that the ETS 2 gene is at the center of these compounded diseases. According to the research published on June 5 in Nature, the ETS2 (Erythroblast Transformation Specific or E-Twenty-Six) gene plays a central role in the various biological processes, as it acts as a regulator of the human inflammatory macrophage and limn the disease mechanism overexpression. The disease-associated locus physically interacts with the ETS2, (in Humans, 29 ETS2 and compared to mouse, 28 ETS2) to macrophage progress during the investigation.

A chromosome 21q22 has been independently linked to inflammatory bowel disease and the gene regulated by ETS2 is actively involved in and activates this inflammatory progresses. Overexpressed ETS2 increases pro-inflammatory cytokine secretion and is essential for human macrophage inflammatory responses.

Through the study investigation, researchers found that MEK inhibition abrogates ETS2-driven inflammation in human macrophages. Potent anti-inflammatory activity was observed that produced the effects of disrupting ETS2 or the chr 21q22 enhancer by MEK inhibition. MEK inhibition reduced inflammatory cytokine release to similar levels of infliximab (an anti-TNF antibody that is widely used for IBD).

IBD (Inflammatory bowel disease) is linked to the ETS2 gene, which according to the CDC, is a term for two conditions (Crohn’s disease and ulcerative colitis), and it is a chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. In the treatment of IBD, MEK inhibition could be a future therapeutic potential for autoimmune diseases.

8% of the US population suffers from this autoimmune disease, 80% of the patients are women, and many of them are hoping for the right treatment with better ways until scientists seek the pathway of this disease to be cured with MEK inhibition or like balancing out of the autophagy macrophage cell activities.

Coree ILBO copyright © 2013-2024, All rights reserved. This material may not be published, broadcast, rewritten, or redistributed in whole or part without the express written permission.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Confirm that you are not a bot - select a man with raised hand: